TSTickerStarGet alerts

Stockholders approve share authorization and 19.99%-or-more issuance

At its November 11, 2026 Special Meeting, GT Biopharma stockholders approved all four proposals, including elimination of obsolete preferred-stock charter references, an increase in authorized common stock from 25,000,000 to 250,000,000, and approval, for purposes of Nasdaq Rule 5635, of the issuance of 19.99% or more of outstanding common stock in connection with a September 14, 2026 Securities Purchase Agreement, Series M Preferred Stock conversion, and warrant exercises. Stockholders also approved an adjournm...

Share this story

Key takeaways

  • All four proposals were approved at the November 11, 2026 Special Meeting.

  • Stockholders approved increasing authorized common stock from 25,000,000 to 250,000,000, with the higher ceiling available at any time on or before November 11, 2027.

  • Stockholders approved, for Nasdaq Rule 5635 purposes, the potential issuance of 19.99% or more of outstanding common stock tied to the September 14, 2026 Securities Purchase Agreement, Series M Preferred Stock conversion, and exercise of Common Stock Warrants and Vesting Warrants.

  • The filing does not disclose the amount, pricing, or exact number of shares issuable under the approved issuance.

  • Stockholders approved removal of charter references to preferred-stock series that are no longer designated, issued, or outstanding.

  • The meeting had a quorum, with 1,146,416 shares represented in person or by proxy, or approximately 55.62% of 2,061,052 eligible shares.

  • Stockholders also approved meeting adjournment authority if a quorum had not been established or other proposals lacked sufficient votes.

Key metrics

Eligible common shares outstandingSeptember 30, 2026 record date
2,061,052 shares
Shares present or representedNovember 11, 2026 Special Meeting
1,146,416 shares
Eligible shares representedNovember 11, 2026 Special Meeting
Approximately 55.62%
Authorized common shares before approved increaseAt any time on or prior to November 11, 2027
25,000,000 shares
Authorized common shares under approved increaseAt any time on or prior to November 11, 2027
250,000,000 shares
Obsolete Preferred Stock Elimination Proposal votesNovember 11, 2026 Special Meeting
For: 1,062,602; Against: 67,623; Abstain: 16,191; Broker non-votes: —
Increase in Authorized Shares Proposal votesNovember 11, 2026 Special Meeting
For: 892,003; Against: 223,266; Abstain: 31,147; Broker non-votes: —
Issuance Proposal votesNovember 11, 2026 Special Meeting
For: 485,607; Against: 49,077; Abstain: 9,592; Broker non-votes: 602,140

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow GTBP in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert